# Sanofi India (NSE: SANOFI) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SANOFI · Pivot · prices to 22 Oct 2026

Sanofi India (NSE: SANOFI) closed at ₹2,845.00 on 22 Oct 2026, up 0.53% on the day. With a market capitalisation of ₹6,552 Cr, it ranks 688th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 21.2× trailing earnings, against a return on equity of 48.0% in FY25. Over the past year the share price has fallen 40.0%. Its 52-week range is ₹2,796.00 (22 Oct 2026) to ₹4,898.00 (29 Oct 2025); the last close is 41.9% below the high. In Q3 FY25, the quarter ended 31 Dec 2024, revenue was ₹515 Cr (−25.8% year on year) and net profit ₹91 Cr (−33.7%), on a consolidated basis. Promoters held 60.40% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,845.00 |
| Market cap | ₹6,552 Cr |
| P/E (trailing) | 21.2 |
| ROE | 48.0% (FY25) |
| ROCE | 52.7% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹4,898.00 (29 Oct 2025) |
| 52-week low | ₹2,796.00 (22 Oct 2026) |
| 1-year return | −40.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q3 FY25 | ₹515 Cr | −25.8% | ₹91 Cr | −33.7% | ₹39.64 |
| Q2 FY25 | ₹524 Cr | −26.7% | ₹82 Cr | −45.9% | ₹35.69 |
| Q1 FY25 | ₹464 Cr | −34.4% | ₹103 Cr | −16.0% | ₹44.81 |
| Q4 FY24 | ₹732 Cr | −0.6% | ₹137 Cr | −28.3% | ₹59.31 |
| Q3 FY24 | ₹694 Cr | — | ₹138 Cr | — | ₹59.79 |
| Q2 FY24 | ₹715 Cr | — | ₹152 Cr | — | ₹65.95 |
| Q1 FY24 | ₹706 Cr | — | ₹123 Cr | — | ₹53.37 |
| Q4 FY23 | ₹737 Cr | — | ₹190 Cr | — | ₹82.78 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,013 Cr | ₹413 Cr |
| FY24 | ₹2,851 Cr | ₹603 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 60.40%
- Foreign institutions: 5.69%
- Domestic institutions: 19.87%
- Non-institutions: 14.04%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Morepen Laboratories](https://app.pivotnow.in/stock/MOREPENLAB) | ₹125.70 | ₹6,888 Cr | 72.7 | — |
| [Supriya Lifescience](https://app.pivotnow.in/stock/SUPRIYA) | ₹848.80 | ₹6,831 Cr | 32.7 | — |
| [Bliss GVS Pharma](https://app.pivotnow.in/stock/BLISSGVS) | ₹638.00 | ₹6,766 Cr | 53.1 | — |
| [Entero Healthcare Solutions](https://app.pivotnow.in/stock/ENTERO) | ₹1,504.20 | ₹6,547 Cr | 57.1 | — |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |
| [Nephrocare Health Services](https://app.pivotnow.in/stock/NEPHROPLUS) | ₹599.90 | ₹6,019 Cr | 74.1 | — |

## Questions and answers

### What is the share price of Sanofi India today?

Sanofi India (NSE: SANOFI) last closed at ₹2,845.00 on 22 Oct 2026. Its 52-week high is ₹4,898.00 and its 52-week low is ₹2,796.00.

### What is the market cap of Sanofi India?

Sanofi India's market capitalisation is ₹6,552 Cr (₹6,552 Cr) at the 22 Oct 2026 close, ranking 688th among the NSE companies Pivot tracks.

### What is the P/E ratio of Sanofi India?

Sanofi India trades at a trailing P/E of 21.2. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 57.1.

### What is the ROE and ROCE of Sanofi India?

Return on equity was 48.0% in FY25 and return on capital employed was 52.7% in FY25 (consolidated figures).

### Is Sanofi India a debt-free company?

Sanofi India is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Sanofi India's latest quarterly results?

For Q3 FY25 (quarter ended 31 Dec 2024), Sanofi India reported revenue of ₹515 Cr, −25.8% year on year, and net profit of ₹91 Cr, −33.7% year on year.

### How has Sanofi India stock performed over the last year?

Sanofi India's share price has fallen 40.0% over the past year, −16.5% over three months and −7.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Sanofi India?

As of 30 Jun 2026: promoters 60.40%, foreign institutions 5.69%, domestic institutions 19.87%, non-institutions 14.04%.

### Who are Sanofi India's competitors?

The listed Pharma & Healthcare companies closest to Sanofi India by market cap are Morepen Laboratories, Supriya Lifescience, Bliss GVS Pharma, Entero Healthcare Solutions, Kovai Medical Center & Hospital and Nephrocare Health Services.

### Is Sanofi India a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Sanofi India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SANOFI against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.